Alzheimer’s disease

Brain & Nerves

Alzheimer’s disease

Alzheimer’s disease is a progressive brain disorder and the leading cause of dementia. It is marked by worsening memory loss, confusion, and changes in thinking and behavior, eventually interfering with daily life and independence. The condition is linked to the buildup of beta-amyloid plaques and tau tangles, which damage and kill brain cells. Risk increases with age, family history, and certain genetic factors, though lifestyle and vascular health also play roles. While there is no cure, medications such as donepezil, rivastigmine, and memantine, along with newer anti-amyloid therapies, can help slow progression and manage symptoms.

AI Summary of Treatment Experiences

Not medical advice.

# Alzheimer's Disease Treatment Summary The Alzheimer's disease treatment landscape includes both established and emerging options with varying clinical benefits. Rivastigmine is rated as a first-line option, particularly valuable for patients with swallowing difficulties or oral medication intolerance due to its transdermal patch formulation. Lecanemab offers modest clinical benefit, slowing cognitive decline by 25-30% in early disease, but requires careful patient selection and MRI monitoring due to risks of brain swelling and microhemorrhages. Aducanumab remains controversial despite reducing amyloid plaques, with limited clinical evidence and safety concerns restricting its use to select patients in clinical trial settings. Memantine, Donepezil, Donanemab, Galantamine, and combined approaches are also listed as treatment options, though reviewers provided limited specific guidance on these alternatives.